The binding affinity of selected candidates was confirmed via biolayer interferometry (BLI), and the therapeutic efficacy of the identified small molecules were biologically validated through <i>in vitro</i> assays on glioma cells.<h4>Results</h4>The druggable MR screening of 140 genes identified EGFR as a key causal target across all glioma subtypes (GBM, non-GBM, and all glioma). The gene discussed is EGFR; the disease is central nervous system cancer.